HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The...
Hence then, the article about cadonilimab pd 1 ctla 4 receives fda clearance for global phase iii first line gastric cancer trial versus nivolumab was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab )
Also on site :
- Monroe County committees vote to accept $160,000 Operation Stonegarden border security grant despite opposition
- 1985 Hit Novel, Written By a 21-Year-Old, Was Inspired By an Elvis Costello Song
- Beloved Romance Author Wants to Turn Jen Hamilton's Divorce Into Her Nex Best Seller — Under One Condition